BeOne Medicines AG (ONC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with significant revenue growth, improved margins, and increased net income. The Q&A reveals confidence in product launches, especially BRUKINSA, and stable pricing. Despite some uncertainties in competitive dynamics and efficacy benchmarks, the overall sentiment is optimistic, supported by strategic advancements and strong guidance. The positive financial results and optimistic outlook suggest a likely stock price increase in the coming weeks.
Key Financial Performance
BRUKINSA Q1 Sales $1.1 billion, representing growth of 38% year-over-year. Reasons for growth include strong performance in all markets and indications, as well as its established position as a foundational BTK inhibitor.
Product Revenue $1.5 billion in Q1, representing 34% year-over-year growth. Growth was driven by strong business momentum across the product portfolio.
BRUKINSA U.S. Sales $761 million in Q1, with volume growth of approximately 28% year-over-year. Growth was driven by strong demand and a mid-single-digit pricing benefit.
TEVIMBRA Revenue 20% year-over-year increase, with sustained market leadership in China and contributions from launch markets outside of China.
XGEVA Revenue $90 million in Q1, showing robust performance. However, biosimilar entrants filed for approval in April, which could lead to enhanced competition.
China Revenue $465 million in Q1, a 17% increase year-over-year, with 5% driven by foreign exchange. Growth was supported by sustained leadership from TEVIMBRA and BRUKINSA.
Europe Revenue $191 million in Q1, representing growth of 64% year-over-year. Growth was supported by foreign exchange (11%) and demand growth for BRUKINSA.
Rest of World Revenue 104% year-over-year growth, driven by market expansions and new launches in key markets such as Japan and Brazil.
Gross Margin Improved to 89% from 85% year-over-year, primarily due to favorable product mix, price, and cost efficiencies.
Operating Expenses Grew by 16% year-over-year, totaling $1.1 billion, reflecting investments to support commercial growth and pipeline advancement.
Income from Operations $250 million in Q1, an increase from $11 million in the prior period, driven by strong revenue growth and improved gross margin.
Net Income $227 million in Q1, with GAAP diluted earnings per ADS of $1.96, reflecting strong operational performance.
Non-GAAP Income from Operations $414 million in Q1, up from $139 million in the prior period, reflecting adjustments for typical items.
Non-GAAP Net Income $375 million in Q1, translating to diluted non-GAAP earnings per ADS of $3.24, reflecting strong financial performance.
Free Cash Flow $161 million in Q1, an increase of $173 million over the prior period, despite typical working capital seasonality.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BRUKINSA: Achieved global leadership in the BTK market with Q1 sales of $1.1 billion, representing 38% growth. Demonstrated superior efficacy and tolerability in CLL treatment, with long-term progression-free survival and overall survival rates.
Sonro: Designed as a next-generation BCL-2 inhibitor with 14x potency and 6x selectivity compared to venetoclax. Early trials show promising efficacy and safety, with potential to disrupt the fixed-duration treatment market.
BTK CDAC: First-in-class therapy showing complete BTK degradation. Achieved a 94.4% overall response rate in Phase I/II trials for heavily pretreated patients. Potential accelerated approval submission in the U.S. for relapsed/refractory CLL expected in the second half of 2026.
Global Expansion: Revenue growth driven by market expansions and new launches in key markets such as Japan and Brazil. Rest of World markets grew 104%.
U.S. Market: BRUKINSA Q1 sales reached $761 million, with 28% volume growth. U.S. remains the largest market, generating $766 million in revenue.
China Market: TEVIMBRA reported a 20% increase in revenue, maintaining market leadership despite competition. China revenue totaled $465 million, a 17% increase year-over-year.
Europe Market: Revenue grew 64%, driven by demand growth for BRUKINSA and foreign exchange benefits. Europe contributed $191 million in revenue.
Financial Performance: Q1 product revenue reached $1.5 billion, a 34% year-over-year growth. Gross margin improved to 89%, reflecting favorable product mix and cost efficiencies.
Pipeline Development: 18 new molecular entities added in the last two years, with a focus on hematology and solid tumors. Sustained innovation with 8-10 NMEs expected annually from 2026 onwards.
Operational Efficiency: Operating expenses grew by 16%, supporting commercial growth and pipeline advancement. Free cash flow increased by $173 million year-over-year.
Solid Tumor Portfolio: Shift from early promise to late-stage execution with multiple programs advancing towards registration. Focus on breast and liver cancers with innovative therapies.
Hematology Franchise: Strengthened with BRUKINSA, Sonro, and BTK CDAC, targeting comprehensive CLL treatment across all stages of the disease.
Selective External Innovation: Acquired an exclusive option for a novel PD-1 VEGF CTLA-4 trispecific, expected to enter the clinic in June, enhancing the solid tumor portfolio.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: BRUKINSA faces competition from other BTK inhibitors like ibrutinib, acalabrutinib, and pirto. The lack of differentiation in efficacy and tolerability for some competitors could challenge BRUKINSA's market position.
Regulatory Hurdles: The company is awaiting U.S. PDUFA decisions for sonro and TEVIMBRA, which could impact their market entry and revenue projections.
Economic Uncertainties: Potential biosimilar competition for XGEVA could lead to pricing pressures and reduced revenue.
Strategic Execution Risks: The company is heavily reliant on the success of its hematology franchise and new product launches like sonro and BTK CDAC. Failure in clinical trials or regulatory approvals could significantly impact growth.
Supply Chain Disruptions: No explicit mention of supply chain issues, but global expansion and new market launches could pose logistical challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: The company has raised its 2026 revenue guidance range by $100 million, now projecting revenue between $6.3 billion to $6.5 billion.
BRUKINSA Performance: BRUKINSA continues to lead the BTK market with strong global sales growth. The company expects continued revenue growth driven by its differentiated long-term data and expanding market share.
Sonro Development: Sonro, a next-generation BCL-2 inhibitor, is expected to disrupt the fixed-duration market. The company anticipates U.S. PDUFA decision soon, EU submission, and ESMO guideline inclusion. Phase III studies are underway, with potential to change the first-line CLL treatment paradigm.
BTK CDAC Development: The BTK CDAC program is advancing with several Phase III trials underway. The company expects a potentially accelerated approval submission in the U.S. for relapsed/refractory CLL in the second half of 2026.
Solid Tumor Portfolio: The company is advancing its solid tumor pipeline with multiple programs moving toward late-stage execution. Key programs include CDK4 inhibitor, B7-H4 ADC, and GPC3 x 4-1BB bispecific, with pivotal trials planned for CEA ADC.
Hematology Franchise: The hematology franchise, including BRUKINSA, Sonro, and BTK CDAC, is expected to drive significant growth and innovation. The company is focused on providing best-in-class therapies for CLL patients.
Global Expansion: The company anticipates growth in all markets, with continued global expansion and contributions from new launches such as zanidatamab and sonro.
HCC Market Opportunity: The company is targeting hepatocellular carcinoma (HCC) with its GPC3 x 4-1BB bispecific program, aiming to address unmet medical needs in this multibillion-dollar market.
Pipeline Development: The company plans to sustain a cadence of 8-10 new molecular entities (NMEs) per year from 2026 and beyond, focusing on innovative therapies across hematology, solid tumors, and immunology.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you contextualize BRUKINSA's superiority versus ibrutinib in ALPINE compared to Lilly's pirto claims?
A:BRUKINSA is the only BTKi to demonstrate superiority to ibrutinib in a head-to-head study. Claims about pirto's performance are questionable due to issues like reliance on investigator assessments instead of IRC data, lack of predefined alpha allocation for subgroups, and small sample sizes. For treatment-naive groups, pirto's claims lack statistical significance and have short follow-up data.
Q:What is the update on BRUKINSA's CELESTIAL-TNCLL trial and the degrader CDAC's efficacy hurdle for accelerated approval?
A:The CELESTIAL trial has dual primary endpoints: uMRD and PFS. PFS is the regulatory endpoint, and uMRD data will be reviewed in Q3. Statistical significance for uMRD is challenging, but PFS benefit is expected. For the degrader CDAC, the efficacy hurdle is a benchmark of 50%-70% depending on the population.
Q:What is the status of BRUKINSA's launch in Europe and the expected launch ramp for the BTK CDAC?
A:BRUKINSA's launch in Europe is in early stages with substantial growth potential. The BTK CDAC launch ramp is expected to follow a typical S-shaped uptake curve, leveraging existing infrastructure for economic efficiency.
Q:What is the progress of the immunology programs, specifically CSU and IRAK4 in RA?
A:The CSU program is moving to Phase II based on encouraging Phase Ib data. The IRAK4 program in RA was discontinued due to emerging new data, and further steps are being analyzed.
Q:What is the company's view on the HH160 (PD-1 VEGF CTLA-4 trispecific) amid competition and its Fc silent strategy?
A:The HH160 molecule targets three pathways and aims to differentiate from bispecifics by adding CTLA-4. The Fc silent strategy is designed to mitigate toxicity while retaining efficacy.
Q:What factors contribute to confidence in revenue performance and net pricing stability for the year?
A:Confidence stems from strong U.S. performance, stable net pricing due to contracting opportunities, and growth across geographies. Nonrecurring gross-to-net adjustments in Q1 are accounted for in guidance.
Q:What is the efficacy bar and opportunity for the GPC3 x 4-1BB bispecific in HCC?
A:The efficacy bar for the pivotal study in second-line HCC is under discussion with health authorities. Early data is encouraging, and the asset shows potential for frontline HCC and other opportunities.
Q:How is sonrotoclax performing in China, and what are the competitive dynamics for its U.S. launch?
A:Sonrotoclax has launched successfully in China, with over 300 hospitals treating patients and inclusion in guidelines for multiple indications. In the U.S., it is expected to be a game-changing medicine with potential guideline inclusion based on strong data.
Q:What can be expected from the CDK4 inhibitor data at ASCO?
A:The ASCO presentation will include data from approximately 60 patients showing strong response rates and improved GI tolerability. Progression-free survival data is still immature.
Q:How is the company balancing operating leverage and growth in R&D?
A:The company aims to drive continuous operating leverage while maintaining growth, focusing on sustainable margin expansion and leveraging its R&D engine for long-term value creation.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the specific competitive dynamics of sonrotoclax's U.S. launch and its potential impact on BRUKINSA or the CLL market. Additionally, the efficacy bar for the GPC3 x 4-1BB bispecific in HCC remains under discussion with health authorities, leaving some uncertainty.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
ASCO
AV
BRUKINSA body
CLL community
CLL patient
CTLA
GPC
HCC study
Lai
NMEs
Pirto
Sonro
VO
XGEVA
approach
approval submission
area depth
bispecific
cancer CDK
class BTK
delta
generation covalent
hazard ratio
house
ibrutinib
increase period
inhibitor Phase
landmark PFS
milestone
momentum
patient study
platform
program stage
program track
separation
signal
survival
tisle
trispecific
tumor portfolio
ONC Transcript
BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
BeOne Medicines AG (ONC) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with significant revenue growth, improved margins, and increased net income. The Q&A reveals confidence in product launches, especially BRUKINSA, and stable pricing. Despite some uncertainties in competitive dynamics and efficacy benchmarks, the overall sentiment is optimistic, supported by strategic advancements and strong guidance. The positive financial results and optimistic outlook suggest a likely stock price increase in the coming weeks.
BeOne Medicines AG (ONC) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call showed strong financial performance with notable revenue and margin growth. The Q&A highlighted BRUKINSA's competitive edge and positive market reaction to Sonro. Despite limited details on pricing and immunology strategy, the overall sentiment remains positive due to strong earnings, optimistic guidance, and a solid pipeline. The lack of market cap data suggests a moderate impact, leading to a positive stock price movement prediction.
BeOne Medicines AG (ONC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
